Login to Your Account



Pharmagene Shares Fall On Failed Phase IIa Study, Lower Guidance

By Nuala Moran


Wednesday, December 29, 2004
LONDON - Shares in Pharmagene plc dropped by one-quarter when the company announced its lead product, PGN0052, failed in a Phase IIa trial in cystic fibrosis and the company warned that 2004 revenues from its drug discovery services would be lower than 2003. (BioWorld International)

To continue reading subscribe now to BioWorld Asia (formerly International)

Learn More about BioWorld Asia (formerly International)

Already a subscriber? Sign In or Buy now to activate your subscription